Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s share price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.31 and traded as high as $1.48. Cortexyme shares last traded at $1.40, with a volume of 44,182 shares trading hands.
Cortexyme Trading Down 1.4 %
The business has a fifty day moving average price of $1.74 and a two-hundred day moving average price of $1.31. The firm has a market capitalization of $42.21 million, a PE ratio of -0.47 and a beta of 1.40.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Read More
- Five stocks we like better than Cortexyme
- Overbought Stocks Explained: Should You Trade Them?
- Airbnb’s Earnings: Sky High Results, Grounded Guidance?
- Dividend Capture Strategy: What You Need to Know
- Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?
- How to Invest in Blue Chip Stocks
- Conflicting Signals: Tempus AI’s Stock Market Rally
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
